{
  "id": 15113516,
  "title": "Grail CEO Joshua Ofman sells $2.74m in company stock",
  "url": "https://urgent.news/2026/10/17/grail-ceo-joshua-ofman-sells-2-74m-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T04:01:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/grail-ceo-joshua-ofman-sells-274m-in-company-stock-93CH-4955196"
  },
  "original_language": "en",
  "account": "On October 15, 2026, GRAIL, Inc. CEO Joshua J. Ofman sold 20,000 shares of the company's common stock, totaling approximately $2,736,944. The sales were made in multiple transactions at prices ranging from $132.67 to $139.17 per share, executed according to a Rule 10b5-1 trading plan adopted on December 2, 2025. Following the sale, Ofman still owns 342,271 shares of GRAIL Inc. common stock. However, GRAIL's stock has declined by around 16% in the past week, closing at $117.81, which is lower than the sale prices. The company is currently considered overvalued by InvestingPro. The FDA Advisory Committee recently approved GRAIL's Galleri multi-cancer early detection test, with a unanimous 10-0 vote on safety and a 6-4 vote on effectiveness. This positive outcome has led several financial firms to adjust their outlooks on GRAIL. TD Cowen increased its price target to $180, Canaccord Genuity raised it to $150, and Mizuho set it to $100, all emphasizing the test's safety and effectiveness. The FDA staff's lack of major concerns has boosted investor confidence.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "German American Bancorp director Andrew Seger buys $100 in shares",
        "url": "https://urgent.news/2026/10/16/german-american-bancorp-director-andrew-seger-buys-100-in-shares",
        "published": "2026-10-16T19:01:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}